ArticleCJC open2022

Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events.

Kevin E Boczar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.